WHO ICTRP trial
A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients…
EUCTR2007-002212-26-FR · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2007-002212-26-FR |
|---|---|
| Public title | A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes - GFM-VOR-2007-1 |
| Scientific title | A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes - GFM-VOR-2007-1 |
| Primary sponsor | Groupe Francophone des Myélodysplasies |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | France |
| Conditions | Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS)as defined by the International Prognostic Scoring System (IPSS). MedDRA version: 9.1 Level: LLT Classification code 10028532 Term: Myelodysplasia |
| Interventions | Trade Name: ZOLINZA Product Name: ZOLINZA Product Code: MK-0683 Pharmaceutical Form: Capsule* |
| Registration date | Jul 30, 2007 |
| Secondary IDs | MK-0683-065 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: